A Phase 1, randomized study to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating single, oral doses of ONC201 and the effects of food on the bioavailability of ONC201 following oral administration in healthy adult subjects - Part A
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Dordaviprone (Primary)
- Indications Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Glioblastoma; Glioma; Liver cancer; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Sarcoma; Small cell lung cancer; Thyroid cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chimerix
- 04 Aug 2021 New trial record